MiNK Therapeutics(INKT) - 2025 Q4 - Annual Results

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2026 MiNK Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation) 149 Fifth Avenue Suite 500 New York, New York 10010 (Address of Principal Executive Offices) (Zip Code) Delaware 001-40908 82-2142067 (Commission File Num ...